Vedanta Biosciences logo

Vedanta Biosciences, Inc.


Vedanta Biosciences Stock

Vedanta Biosciences is a biotechnology company that is working to provide doctors and patients with an entirely new option to treat human diseases: medicines based on live bacterial consortia that can colonize the human intestine.

Management Team

Bernat Olle, Ph.D. Chief Executive Officer
Dan Couto Chief Operating Officer
Jeffrey Silber, MD Chief Medical Officer
Mark Mullikin Chief Financial Officer

Funding Information


PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation

VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis. Vedanta's pipeline also includes VE303, its Phase 3 ready therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infection as well as additional candidates being evaluated for inflammatory bowel diseases and Gram-negative infections.

Vedanta secures fast track designation for oral C. diff drug

After a recent $106.5m fundraise, the designation marks another milestone for the company set to start a Phase III study later this year.

Vedanta Biosciences wins FDA fast track designation for Clostridioides difficile treatment

Vedanta Biosciences has obtained fast track designation from the US Food and Drug Administration (FDA) for its live biotherapeutic VE303, a preventative treatment for recurrent Clostridioides difficile infection (CDI).

Vedanta Biosciences raises $106.5M for microbiome therapy

Vedanta Biosciences, which is developing a potential new category of oral therapies based on defined bacterial consortia, has raised $106.5M.

Funding and study to support treatment to stop recurrent infection and ulcerative colitis

A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).